相关实验视频
Updated: Jun 25, 2025

05:48
Rapid Generation of Amyloid from Native Proteins In vitro
Published on: December 5, 2013
6.2K
粉样纤维细胞毒性和相关疾病
Sabereh Saremi1, Khosro Khajeh1
1Department of Biochemistry, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran.
概括
粉样性疾病源于错误折叠的蛋白质形成有毒纤维和寡合体,导致细胞损伤. 目前缺乏治疗方法,突出显示急需对粉样粉症的起源和病理学的研究.
科学领域:
- 生物化学 生物化学
- 细胞生物学 细胞生物学
- 病理学 病理学 病理学
背景情况:
- 错误折叠的蛋白质聚合成不溶性粉样蛋白纤维,破坏细胞功能,导致粉样蛋白疾病.
- 错误折叠的蛋白质的寡合形式越来越被认为是特别具有细胞毒性的物种.
- 氨基粉症的发病包括细胞中断,如不平衡,线粒体功能障碍和氧化应激.
研究的目的:
- 阐明粉样蛋白疾病的基本概念.
- 探索非典型的粉样沉积物在疾病病理学中的作用.
- 强调迫切需要对粉样粉症的起源和治疗开发进行研究.
主要方法:
- 文献综述和对蛋白质错折和粉样蛋白形成现有研究的综合.
- 对粉胺诱导的细胞毒性背后的细胞机制的分析.
- 为了解粉样蛋白疾病病理学的概念框架的开发.
主要成果:
- 粉样蛋白纤维和寡合体是粉样蛋白疾病中的关键病理实体.
- 细胞功能障碍,包括不平衡和线粒体损伤,有助于细胞毒性.
- 目前对粉样症的治疗策略是不够的.
结论:
- 粉样蛋白疾病是由于缺乏有效治疗方法而造成的重大未满足的医疗需求.
- 了解amyloidosis的起源和病理学对于开发新型治疗干预措施至关重要.
- 对非典型的粉样蛋白沉积物的进一步研究可能会揭示新的治疗点.
更多相关视频
00:15Interactions with and Membrane Permeabilization of Brain Mitochondria by Amyloid Fibrils
Published on: September 28, 2019
5.9K
10:10Use of Two Dimensional Semi-denaturing Detergent Agarose Gel Electrophoresis to Confirm Size Heterogeneity of Amyloid or Amyloid-like Fibers
Published on: April 26, 2018
9.8K
相关概念视频
Amyloid Fibrils
9.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.5K
Alzheimer's Disease: Overview
462
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
462